Trial reportJournal of cosmetic dermatology2026
A Multicenter Trial of an Enhanced Serum Comprised of 13 Plant-Based Adaptogens Targeting Skin Quality in Females Impacted by Hormonal Decline.
Trial report in Journal of cosmetic dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectivesTo assess the effectiveness and tolerability of a serum comprised of plant-based adaptogens (MYS-REV) for visible improvements in skin changes caused by hormonal fluctuations associated with perimenopause and postmenopause in women. STUDY DESIGNS: A 16-week open-label multicenter study evaluated the efficacy and tolerability of twice-daily application of MYS-REV in females, aged ≥ 46 years, Fitzpatrick skin type (FST) I-VI, with fine-to-moderate depth lines and wrinkles, mild-to-moderate elastosis, and crepey skin. Investigators assessed improvements in depth and number of lines/wrinkles, elastosis, and crepey skin. Additionally, investigators assessed improvements in appearance of skin dullness, skin roughness/texture, erythema, uneven pigmentation, and pore size, along with objective changes in skin hydration and transepidermal water loss (TEWL), all over 16 weeks. Tolerability and subject self-assessment were assessed over 16 weeks.
resultsAt 16 weeks, twice-daily use of MYS-REV demonstrated mean percent improvements in elastosis/crepey skin, lines/wrinkles, skin hydration, and TEWL, and in erythema, dullness, texture/roughness, pore size, and uneven pigmentation (all p < 0.0001). All AEs were mild with no study discontinuations owing to any AE. Subjects reported high levels of satisfaction with MYS-REV beginning as early as 4 weeks and continuing through Week 16.
conclusionsThis study demonstrated that twice-daily application of MYS-REV visibly improves skin affected by menopause-related hormonal fluctuations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.